Cambridge Innovation Capital

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatment approaches. This enables patients to access effective and safe treatments for neurological, inflammatory, and oncological conditions.

Salience Labs develops hybrid photonic-electronic chips for AI applications. Founded on over a decade of research from Oxford and Münster universities, they specialize in silicon photonics to address AI data center infrastructure demands. Their flagship product is an optical switch designed to facilitate low-latency, high-bandwidth networking between compute nodes, accelerating job completion while reducing power consumption.

Forefront RF is a semiconductor company specializing in radio frequency technology. Its core product enables simpler designs for multi-band smartphones, wearables, and IoT devices, enhancing global accessibility and signal reception.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Nuclera specializes in accelerating drug discovery by providing a protein prototyping system. Its eProtein Discovery™ platform enables scientists to rapidly produce and test proteins for research purposes.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Seldon empowers machine learning engineering teams to swiftly transition from research & development to production, achieving proven efficiency improvements. It serves large enterprises across various sectors and regions, including prominent players in technology, pharmaceuticals, automotive, finance, and retail. Seldon's open-source projects are widely adopted for model serving, explanations, and monitoring.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Founded in 2015, Carrick Therapeutics is a biopharmaceutical company based in Dublin, Ireland. It specializes in developing innovative cancer therapeutics that target molecular pathways driving aggressive and resistant forms of cancer, aiming to transform cancer treatment.

Cambridge GaN Devices develops gallium nitride based power devices and transistors designed to improve energy efficiency in power electronics. The company designs, creates, and commercializes GaN-based semiconductors that achieve faster switching, lower energy losses, and smaller form factors compared with traditional silicon devices while delivering higher power density. Its products are intended for applications in sectors such as renewable energy, electric vehicles, and consumer electronics, enabling compact and more efficient power conversion and energy management. The company collaborates with industry partners to drive innovation and accelerate adoption of GaN technology in the power semiconductor market.

Unlikely AI is an innovative company focused on advancing artificial intelligence technology through a unique and bold approach. The company develops a product-centric platform that can engage with users and provide explanations, facilitating the creation of AI products that perform tasks previously deemed impossible for computers. By pushing the boundaries of AI capabilities, Unlikely AI aims to reshape the interaction between humans and machines, contributing to the ongoing evolution of the field.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

Salience Labs develops hybrid photonic-electronic chips for AI applications. Founded on over a decade of research from Oxford and Münster universities, they specialize in silicon photonics to address AI data center infrastructure demands. Their flagship product is an optical switch designed to facilitate low-latency, high-bandwidth networking between compute nodes, accelerating job completion while reducing power consumption.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to address the underlying causes of mitochondrial dysfunction through a thorough understanding of mitochondrial mechanisms. By creating innovative treatments, Pretzel Therapeutics seeks to provide effective solutions for a range of diseases, particularly those related to aging. The company is dedicated to advancing the field of mitochondrial medicine and improving patient outcomes through targeted therapeutic approaches.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Origami is a technology company focused on enabling a green energy transition through intelligent trading, automation, and portfolio optimization. Its platform combines real-time data and machine learning to support energy companies in managing complex physical, financial, and contractual positions across power production, planning, and energy trading workflows. The company offers a modular suite that integrates asset-level operations and market opportunities, enabling asset owners and operators to capture opportunities across markets and geographies and to generate risk-adjusted returns from a portfolio of assets.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Seldon empowers machine learning engineering teams to swiftly transition from research & development to production, achieving proven efficiency improvements. It serves large enterprises across various sectors and regions, including prominent players in technology, pharmaceuticals, automotive, finance, and retail. Seldon's open-source projects are widely adopted for model serving, explanations, and monitoring.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.

Sense Biodetection Limited is a molecular diagnostics company based in Abingdon, United Kingdom, established in 2013. The company specializes in developing user-centered, handheld diagnostic tests aimed at enhancing healthcare decisions and processes, particularly in the areas of infections and oncology. Its flagship product, True Point-of-Care, utilizes advanced molecular methods, including polymerase chain reaction (PCR), to deliver rapid and accurate results. This capability allows clinics and medical professionals to detect infections swiftly and make informed treatment decisions in a decentralized healthcare setting, ultimately improving patient outcomes.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Founded in 2015 and headquartered in Cambridge, UK, Morphogen-IX is a biotechnology company focused on developing novel therapies for pulmonary arterial hypertension (PAH). The company's core expertise lies in bone morphogenetic proteins (BMPs), with a particular emphasis on BMP9 and BMP10. Its semi-virtual model combines an experienced team of drug discovery professionals with outsourced development programs, aiming to maximize capital efficiency while maintaining high-quality research.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

CEDAR Audio is a Cambridge, UK-based company focused on audio restoration and speech enhancement for film, post-production, television and radio broadcasting, CD and DVD mastering, libraries and archives, and audio forensic investigations. Established in 1988 following five years of research funded by the British Library National Sound Archive, it maintains strong academic links with Cambridge University and counts two Cambridge University professors and a director of studies among its directors. The company develops and manufactures hardware-based restoration systems and pursues ongoing research into new techniques in audio restoration and speech enhancement, while prioritizing high-quality customer support and industry recognition.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, specializing in advanced audio processing technology. Founded in 2017, AudioTelligence focuses on developing software that enhances the clarity and intelligibility of audio captured from multiple microphones, addressing the challenges posed by loud background noise in conversations. The company employs a data-driven technique known as blind audio signal separation, which significantly outperforms traditional methods such as beamforming and deep neural networks. This innovative technology aims to improve automatic speech recognition (ASR) systems, enabling businesses to provide clearer and more understandable speech for both users and voice-activated devices.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Nstream is a technology company that specializes in advanced analytics software designed to process data at the edge of networks. Founded in 2015 and headquartered in San Jose, California, Nstream offers products like Swim EDX and Swim Continuum, which enable organizations to gain real-time insights and predictions from streaming data. The company focuses on providing solutions for various sectors, including original equipment manufacturers, service providers, enterprises, and Internet of Things (IoT) vendors. Nstream's platform combines edge computing, machine learning, and self-training digital twins, allowing businesses to enhance decision-making and operational efficiency. By leveraging a unique stateful architecture, its products eliminate traditional database latency, ensuring rapid access to contextual data and facilitating effective operational decision support.

Undo Ltd., established in 2005, specializes in developing debugging tools for software developers. Its flagship product, LiveRecorder, records and replays software execution to aid in identifying and fixing programming errors. UndoDB, another key offering, provides an interactive reversible debugger for C/C++ on Linux and Android platforms. The company serves industries such as data management, networking, electronic design automation, and finance, with offices in Cambridge, UK, and San Francisco, CA.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Origami is a technology company focused on enabling a green energy transition through intelligent trading, automation, and portfolio optimization. Its platform combines real-time data and machine learning to support energy companies in managing complex physical, financial, and contractual positions across power production, planning, and energy trading workflows. The company offers a modular suite that integrates asset-level operations and market opportunities, enabling asset owners and operators to capture opportunities across markets and geographies and to generate risk-adjusted returns from a portfolio of assets.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Secondmind Ltd. is a software development company based in Cambridge, United Kingdom, founded in 2016. The company specializes in machine learning technology to assist automotive innovators in designing cleaner, more sustainable vehicles. Its core product, the Secondmind Decision Engine, is a cloud-based platform that empowers users to predict, plan, and manage complex decisions while navigating the intricacies of engineering design, particularly during the transition to electrification. By leveraging advanced machine learning algorithms, Secondmind aims to enhance the design, development, and driving experience of vehicles, ultimately contributing to the goal of carbon-neutral mobility. Formerly known as Prowler.io Limited, the company rebranded in October 2020 and has established itself as a leader in applying practical machine learning research to the automotive sector.

Z Factor Limited is a drug discovery company established in 2015 with a focus on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company is dedicated to designing innovative treatments that address the misfolding of the Z variant of alpha-1-antitrypsin. This condition presents significant medical challenges, and current treatment options are largely restricted to lung or liver transplantation and augmentation therapy. By targeting the underlying causes of the disease, Z Factor aims to fulfill a critical unmet medical need in the field of respiratory and liver health.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Founded in 2016, Exvastat is a preclinical-stage pharmaceutical company developing a treatment for Acute Respiratory Distress Syndrome (ARDS) using a repurposed drug. This treatment has the potential to significantly reduce ARDS mortality and morbidities, thereby decreasing healthcare costs.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Undo Ltd., established in 2005, specializes in developing debugging tools for software developers. Its flagship product, LiveRecorder, records and replays software execution to aid in identifying and fixing programming errors. UndoDB, another key offering, provides an interactive reversible debugger for C/C++ on Linux and Android platforms. The company serves industries such as data management, networking, electronic design automation, and finance, with offices in Cambridge, UK, and San Francisco, CA.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Founded in 2015, Carrick Therapeutics is a biopharmaceutical company based in Dublin, Ireland. It specializes in developing innovative cancer therapeutics that target molecular pathways driving aggressive and resistant forms of cancer, aiming to transform cancer treatment.

Founded in 2011, PervasID specializes in developing wide area RFID systems that offer location capabilities based on the EPC Class1 Gen2 standard. The company's technology enables accurate tracking of goods and assets across various industries.

Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.

Founded in 2014, CMR Surgical designs and manufactures medical devices for minimal access surgery. Its flagship product is Versius, a surgical robotic system that enhances laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback during operations.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Origami is a technology company focused on enabling a green energy transition through intelligent trading, automation, and portfolio optimization. Its platform combines real-time data and machine learning to support energy companies in managing complex physical, financial, and contractual positions across power production, planning, and energy trading workflows. The company offers a modular suite that integrates asset-level operations and market opportunities, enabling asset owners and operators to capture opportunities across markets and geographies and to generate risk-adjusted returns from a portfolio of assets.

Audio Analytic Ltd., established in 2008, specializes in developing sound recognition software for consumer electronics. Based in Cambridge, UK, with an office in San Francisco, the company offers embedded software platforms, ai3™ and ai3-nano™, which enable products like smart speakers, video doorbells, and earbuds to understand and respond to their environment through sound. Their software is licensed to leading consumer tech companies, providing context-based intelligence to enhance user experiences.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Founded in 2015 and headquartered in Cambridge, UK, Morphogen-IX is a biotechnology company focused on developing novel therapies for pulmonary arterial hypertension (PAH). The company's core expertise lies in bone morphogenetic proteins (BMPs), with a particular emphasis on BMP9 and BMP10. Its semi-virtual model combines an experienced team of drug discovery professionals with outsourced development programs, aiming to maximize capital efficiency while maintaining high-quality research.

Jukedeck is an artificial intelligence–driven music composition company that develops tools to create original music for videos and apps. It trains deep neural networks to understand music composition and to automatically generate and tailor scores for different scenes, moods, and timing. The platform includes an API that gives developers access to a library of royalty-free music and backing tracks, enabling users to browse, edit, and integrate music into their apps and videos. By interpreting video inputs, Jukedeck aims to provide personalized music solutions for individuals and businesses, supporting creative workflows without licensing hurdles.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.

Abcodia is a biotechnology company specializing in the discovery and validation of molecular biomarkers for disease diagnosis and screening, with a particular focus on cancer. Founded in 2010 and headquartered in Cambridge, UK, Abcodia utilizes its unique longitudinal serum biobank and collaborations with academic institutions like UCL, technology platform providers, and leading diagnostic companies to support the entire diagnostic development process. The company offers Roca Test solutions for early ovarian cancer detection, serving customers across multiple states in the US and the United Kingdom.

Undo Ltd., established in 2005, specializes in developing debugging tools for software developers. Its flagship product, LiveRecorder, records and replays software execution to aid in identifying and fixing programming errors. UndoDB, another key offering, provides an interactive reversible debugger for C/C++ on Linux and Android platforms. The company serves industries such as data management, networking, electronic design automation, and finance, with offices in Cambridge, UK, and San Francisco, CA.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Pragmatic specializes in ultra-low-cost flexible electronics. Its FlexICs, thinner than human hair, enable innovative solutions by embedding circuits invisibly into objects. The company offers a FlexIC Foundry service for custom application-specific devices and standard FlexIC products for mass market use cases like RFID and NFC. Pragmatic's revolutionary FlexLogIC production system facilitates high-volume manufacturing at significantly lower costs compared to traditional silicon IC fabs. Headquartered in Cambridge, UK, with a billion-unit production facility in Sedgefield, the company serves diverse markets such as consumer goods, retail, healthcare, and gaming.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Origami is a technology company focused on enabling a green energy transition through intelligent trading, automation, and portfolio optimization. Its platform combines real-time data and machine learning to support energy companies in managing complex physical, financial, and contractual positions across power production, planning, and energy trading workflows. The company offers a modular suite that integrates asset-level operations and market opportunities, enabling asset owners and operators to capture opportunities across markets and geographies and to generate risk-adjusted returns from a portfolio of assets.

Jukedeck is an artificial intelligence–driven music composition company that develops tools to create original music for videos and apps. It trains deep neural networks to understand music composition and to automatically generate and tailor scores for different scenes, moods, and timing. The platform includes an API that gives developers access to a library of royalty-free music and backing tracks, enabling users to browse, edit, and integrate music into their apps and videos. By interpreting video inputs, Jukedeck aims to provide personalized music solutions for individuals and businesses, supporting creative workflows without licensing hurdles.

Imagen Ltd, established in 1991 and based in Willingham, UK, specializes in designing and developing media archive management solutions. The company offers three primary products: Imagen2, a comprehensive media asset management and publishing system; ImagenCloud, a cloud-based solution for managing and publishing videos and images; and Orbital, a compliance recording system. Its client portfolio includes prominent organizations such as the Ministry of Defence, The Police, BBC, ITN, Imperial War Museum, British Telecom, and British Pathé. Imagen Ltd operates under its current name since August 2015, following a rebrand from Cambridge Imaging Systems Limited.